Skip to content

To check the relative ability of Vidavance to increase the level of glucose in the blood.

Glycemic Index of an anti-diabetic oral nutritional supplement Vidavance

Status
Active, not recruiting
Phases
Phase 4
Study type
Observational
Source
CTRI
Registry ID
CTRI/2022/08/044917
Enrollment
30
Registered
2022-08-25
Start date
Unknown
Completion date
Unknown
Last updated
2023-01-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E11- Type 2 diabetes mellitus

Interventions

Intervention1: Vidavance: 53.77 g of Vidavance containing 23.85 g available carbohydrates
3.5 scoops in 90 mL of luke warm water / milk
add 90 mL more before consumption Duration of intervention - 1 day Control Intervention1: Reference food: 27.5 g of glucose monohydrate dissolved in 125 ml of water Duration of intervention - 3 day

Sponsors

Dr Chetan Mehndiratta
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Diabetic subjects ages 18-60 years Fasting >120 mg / dL No known food allergy or intolerance Not taking any medications known to affect glucose tolerance.

Exclusion criteria

Exclusion criteria: Subjects on special diet restriction Pregnant and lactating mothers with a known history of diabetes mellitus Presence of disease or drug(s) that may influence digestion and absorption of nutrients and a major medical or surgical event in the last 3 months

Design outcomes

Primary

MeasureTime frame
Estimation of the GI value of test product, using the iAUC Timepoint: CGM data will be obtained at -5, 0, 15, 30, 45, 60, 90, and 120 minutes after the start of the test meal.

Secondary

MeasureTime frame
Look for the hypoglycemic event (Blood sugar level less than 70 mg/dl for a period within 24 hrs) Look for hyperglycemic event (Blood sugar level more than 180 mg/dl for a period of 24 hrs) Look for the glycemic variation in the subjects Calculate the Time in Range (TIR) (the time spent by the subject in the target blood sugar range of 70-180 mg/dl) Timepoint: Within 24 hours of Continuous Glucose Monitoring (CGM)

Countries

India

Contacts

Public ContactDr Mudit Sabharwal

Dharma Diabetes clinics

drmuditsabharwal@gmail.com9811255505

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026